Actuate Therapeutics, Inc. Common stock
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Actuate Therapeutics, Inc. Common stock's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Actuate Therapeutics, Inc. Common stock made a loss over the last year. Actuate Therapeutics, Inc. Common stock owes $0.81 for every $1 it owns. Actuate Therapeutics, Inc. Common stock made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossActuate Therapeutics, Inc. Common stock made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
12.53The share price is 12.53 times Actuate Therapeutics, Inc. Common stock's book value per share, higher than 89% of Healthcare companies in United States.
Market cap
$12 MThe total market value of all of Actuate Therapeutics, Inc. Common stock's shares at today's price (share price × number of shares), smaller than 85% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$1 MWhat Actuate Therapeutics, Inc. Common stock would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.04Net worth divided by the number of shares. The share price of $0.52 is 12.5 times this, which is the P/B above.
Owes vs Owns
0.81×Actuate Therapeutics, Inc. Common stock owes $0.81 for every $1 it owns (high), higher than 78% of Healthcare companies in United States.
Dividend yield
NoneActuate Therapeutics, Inc. Common stock does not currently pay a dividend.
Profit growth
LossActuate Therapeutics, Inc. Common stock made a loss in each of the last two years.
Interest cover
Not coveredActuate Therapeutics, Inc. Common stock's operating profit did not cover its interest costs in the year to Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Actuate Therapeutics, Inc. Common stock: $12 M ÷ $1 M (30 Jun 2026) = 12.5.
How much does Actuate Therapeutics, Inc. Common stock owe compared with what it owns?
Actuate Therapeutics, Inc. Common stock owes $0.81 for every $1 it owns (high), higher than 78% of Healthcare companies in United States.
Does Actuate Therapeutics, Inc. Common stock pay a dividend?
No. Actuate Therapeutics, Inc. Common stock does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.